Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
暂无分享,去创建一个
Quanxin Long | X. Tang | Qiuling Shi | Qin Li | H. Deng | Jun Yuan | Jie-Li Hu | W. Xu | Yong Zhang | Fa-jin Lv | Kun Su | Fan Zhang | Jiang Gong | Bo Wu | Xia-mao Liu | Jin-jing Li | Jing-Fu Qiu | Juan Chen | A. Huang | K. Su | Quan-xin Long | Xiao-jun Tang | Bo Wu
[1] G. Gao,et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[2] W. Cao,et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. , 2007, The New England journal of medicine.
[3] Lin‐Fa Wang,et al. Duration of Antibody Responses after Severe Acute Respiratory Syndrome , 2007, Emerging infectious diseases.
[4] P. Marik,et al. A Descriptive Study , 2015 .
[5] S. Park,et al. Viral Load Kinetics of MERS Coronavirus Infection. , 2016, The New England journal of medicine.
[6] A. Tamin,et al. Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus , 2016, Emerging infectious diseases.
[7] Kyoung-Ho Song,et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 , 2017, Emerging infectious diseases.
[8] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[9] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[10] J. Low,et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.
[11] N. Linton,et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) , 2020, International Journal of Infectious Diseases.
[12] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[13] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[14] M. Lipsitch,et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.
[15] Shashwat Shivam,et al. Modeling shield immunity to reduce COVID-19 epidemic spread , 2020, Nature Medicine.
[16] Quanyi Wang,et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients , 2020, medRxiv.
[17] Mengfeng Li,et al. Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers , 2020, medRxiv.
[18] Wenzhen Zhu,et al. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes , 2020, Investigative radiology.
[19] Jun Yuan,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[20] Philip L. Felgner,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, medRxiv.
[21] Jian-ming Wang,et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China , 2020, Science China Life Sciences.
[22] O. F. Norheim. Protecting the population with immune individuals , 2020, Nature Medicine.
[23] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[24] G. Chowell,et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[25] Kari Stefansson,et al. Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.
[26] Y. Wen,et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.
[27] Xinquan Wang,et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.
[28] Vineet D. Menachery,et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.
[29] Steven Y. C. Tong,et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.
[30] Jian-ming Wang,et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China , 2020, Science China Life Sciences.
[31] E. Petersen,et al. SARS-CoV-2 shedding and infectivity , 2020, The Lancet.
[32] Yan Bai,et al. Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.
[33] A. Phelan,et al. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges , 2020, The Lancet.